Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: A "real world" study

Archives of Gerontology and Geriatrics

Volumn 38, Issue SUPPL., 2004, Pages 297-307

  Mossello, E ^a   Tonon, E ^b   Caleri, V ^a   Tilli, S ^a   Cantini, C ^b   Cavallini, M C ^a   Bencini, F ^b   Mecacci, R ^b   Marini, M ^b   Bardelli, F ^b   Sarcone, E ^a   Razzi, E ^a   Biagini, C A ^b   Masotti, G ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Azienda USL 3   (Italy)

Author keywords

Cholinesterase inhibitors (ChEI); Donepezil; Galantamine; Rivastiamine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE; CARBAMIC ACID DERIVATIVE; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT WITHDRAWAL; COGNITIVE DEFECT; HOSPITALIZATION; NEUROPSYCHOLOGICAL TEST;

AGED; ALZHEIMER DISEASE; CARBAMATES; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; FEMALE; GALANTAMINE; HUMANS; INDANS; MALE; NEUROPSYCHOLOGICAL TESTS; PHENYLCARBAMATES; PIPERIDINES; SEVERITY OF ILLNESS INDEX;

EID: 20844463793     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2004.04.040     Document Type: Article

References (19)

1. Auriacombe, S., Pere, J.J., Loria-Kanza, Y. and Vellas B. (2002): Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr. Med. Res. Opin., 18, 129-138.
2. Bullock, R. and Connolly, C. (2002): Switching cholinesterase inhibitor therapy in Alzheimer's disease, donepezil to rivastigmine, is it worth it? Int. J. Geriatr. Psychiatry, 17, 288-289.
3. Corey-Bloom, J., Anand, R. and Veach, J., for the ENA 713 B 532 Study Group (1998): A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartarate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int. J. Geriatr. Psychopharmacol.,1, 55-65.
4. Folstein, M.F., Folstein, S.E. and Mc High, P.R. (1975): Mini-mental state: a practical method for grading the cognitive status of patients for the clinician. J. Psychiatric Res., 12, 189-198.
5. Jorm, A.F. and Jolley, D. (1998): The incidence of dementia: a meta analysis. Neurology, 51, 728-733.
6. Katz, S., Ford, A.B., Moskowitz, R.W., Jackson, B.A. and Jaffe, M.W. (1963): The index of ADL: a standardized measure of biological and psychosocial function. J. Am. Med. Assoc.,185, 914-919.
7. Lanctôt,K.L., Herrmann, N., Kenneth, K.Y., Khan, L.R., Liu, B.A., LouLou, M.M. and Einarson, T.R. (2003): Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. Can. Med. Assoc. J., 169, 557-564.
8. Lawton, M.P. and Brody, E.M. (1969): Assessment of older people: self maintaining and instrumental activities of daily living. Gerontologist, 9, 179-186.
9. Lopez, O.L., Becker, J.T., Wisniewski, S., Saxton, J., Kaufer, D.I. and Dekosky, S.T. (2002): Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry, 72, 310-314.
10. McKhann,G., Drachma, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M. (1984): Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939-944.
11. Mohs, R.C., Doody, R.S., Morris, J.C., Ieni, J.R., Rogers, S.L., Perdomo, C.A., Pratt, R.D. and "312" Study Group (2001): A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology, 57, 481-488.
12. Raskind, M.A., Peskind, E.R., Wessel, T., Yuan, W. and the Galantamine USA-1 Study Group (2000): Galantamine in AD. A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology, 54, 2261-2268.
13. Rogers, S.L., Doody, R.S., Pratt, R.D. and Ieni, J.R. (2000): Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur. Neuropsychopharmacol., 10, 195-203.
14. Rösler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H.B., Hartman, R. and Gharabawi, M. (1999): Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Br. Med. J., 318, 633-638.
15. Salmon, D.P., Thal, L.J., Butters, N. and Heindel, W.C. (1990): Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology, 40, 1225-1230.
16. Tariot, P.N., Solomon, P.R., Morris, J.C., Kershaw, P., Lilienfeld, S., Ding, C. and the Galantamine USA -10 Study Group (2000): A 5-month, randomized, placebo -controlled trial of galantamine in AD. Neurology, 54, 2269-2276.
17. Tariot, P.N., Cummings, J.L., Katz, I.R., Mintzer, J., Perdomo, C.A., Schwam, E.M. and Whalen, E. (2001): A randomized, double -blind, placebo -controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J. Am. Geriatr. Soc. 49, 1590-1599.
18. Wilkinson, D.G., Passmore, A.P., Bullock, R., Hopker, S.W., Smith, R., Potocnik, F.C., Maud, C.M., Engelbrecht, I., Hock, C., leni, J.R. and Bahra, R.S. (2002): A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int. J. Clin. Pract., 56, 441-446.
19. Winblad, B., Engedal, K., Soininen, H., Verhey, F., Waldemar, G., Wimo, A., Wetterholm, A.-L., Zhang, R., Haglund, A., Subbiah, P. and the Donepezil Nordic Study Group (2001): A 1-year, randomized, placebo -controlled study of donepezil in patients with mild to moderate AD. Neurolony, 57, 489-495.